WA
SMMT icon

WPG Advisers’s Summit Therapeutics SMMT Stock Holding History

WPG Advisers’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.4K Buy
439
+151
+52% +$2.68K ﹤0.01% 900
2026
Q1 		$5.46K Hold
288
– – ﹤0.01% 850
2025
Q4 		$5.04K Buy
+288
New +$5.42K ﹤0.01% 901

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

WPG Advisers's SMMT Position: Q2 2026 in Review

WPG Advisers increased its Summit Therapeutics (SMMT) stake by 52% in Q2 2026, buying an estimated $2.68K and bringing the position to 439 shares worth $6.4K. The position accounts for ﹤0.01% of the portfolio, ranked #900.

WPG Advisers first reported a position in SMMT in Q4 2025 and has held it in 3 quarters since. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • WPG Advisers held 439 shares of Summit Therapeutics worth $6.4K as of Q2 2026.
  • WPG Advisers bought 151 Summit Therapeutics shares in Q2 2026, an estimated $2.68K.
  • Summit Therapeutics made up ﹤0.01% of WPG Advisers's portfolio in Q2 2026, its #900 holding.
  • WPG Advisers first reported a position in Summit Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on WPG Advisers's 13F filing for Q2 2026, filed 6 Aug 2026.